Displaying 261 - 280 of 671
FTC Imposes Conditions on Quaker Chemical Corp.’s Acquisition of Houghton International Inc.
After Healthcare System Sanford Health Abandons Acquisition of North Dakota Healthcare Provider Mid Dakota Clinic, FTC Dismisses Case from Administrative Trial Process
Sanford Health/Sanford Bismarck/Mid Dakota Clinic, In the Matter of
The FTC issued an administrative complaint and authorized a federal court action to block Sanford Health's proposed acquisition of Mid Dakota Clinic, alleging that the deal would vioated antitrust law by significantly reducing competition for adult primary care physician services, pediatric services, obstetrics and gynecology services, and general surgery physician services in the greater Bismarck and Mandan metropolitan area. The FTC, jointly with the Office of the Attorney General of North Dakota, filed a complaint in federal district court seeking a temporary restraining order and preliminary injunction to stop the deal and maintain the status quo pending an administrative trial on the merits. According to the complaint, Sanford and Mid Dakota are each other's closest rivals in the four-county Bismarck-Mandan region of North Dakota, and the merger would create a group of physicians with at least 75 to 85 percent share in the provision of adult primary care physician services, pediatric services, obstetrics and gynecology services. On July 9, 2019, after Sanford abandoned its acquisition of Mid Dakota Clinic, the Commission announced that it voted 5-0 to dismiss the case.
FTC Approves Final Order Imposing Conditions on Merger of Titanium Dioxide Companies Tronox Limited and Cristal
Tronox/Cristal USA, In the Matter of
The FTC issued an administrative complaint (and authorized staff to seek a TRO and PI which have not been filed) challenging the merger of two top suppliers of chloride process titanium dioxide (TiO2), a white pigment used in a wide variety of products including paint, industrial coatings, plastic, and paper. The FTC’s administrative complaint charges that Tronox Limited’s proposed acquisition of competitor Cristal, for $1.67 billion and a 24 percent stake in the combined entity, would violate the antitrust laws by significantly reducing competition in the North American market (comprised of the United States and Canada) for chloride process titanium dioxide. The FTC alleges that the acquisition, if consummated, would increase the risk of coordinated action among the remaining competitors, and increase the risk of future anticompetitive output reductions by Tronox.
Administrative Law Judge Upholds FTC’s Complaint Challenging Consummated Merger of Companies that Make Microprocessor Prosthetic Knees
Tronox/Cristal USA; Analysis of Agreement Containing Consent Orders To Aid Public Comment
FTC Requires Divestitures by Tronox and Cristal, Suppliers of Widely Used White Pigment, Settling Litigation over Proposed Merger
FTC Approves Final Order Imposing Conditions on Merger of Fresenius Medical Care AG & KGaA and NxStage Medical, Inc.
FTC Issues Modified Final Order Imposing Conditions on Merger of International Industrial Gas Suppliers Praxair, Inc. and Linde AG
FTC Approves Supervalu Inc.’s Application to Sell 2 Supermarkets Operating under the Shop ’n Save Banner in Virginia and West Virginia
FTC Approves Final Order Imposing Conditions on Joint Venture among Three Producers of PET Resin
Corpus Christi Polymers LLC, et al., In the Matter of
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that three PET resin producers’ proposed $1.1 billion joint acquisition out of bankruptcy of an under-construction PET production facility would violate federal antitrust law.
FTC Approves Application from Praxair and Linde for Sale of an Industrial Gases Plant to LyondellBasell Acetyls, LLC
FTC Approves Final Order Imposing Conditions on Penn National Gaming, Inc.’s Acquisition of Pinnacle Entertainment, Inc.
Statement of Chairman Simons, Commissioner Phillips, and Commissioner Wilson Concerning the Proposed Acquisition of NxStage Medical, Inc. by Fresenius Medical Care AG & Co. KGaA
Statement of Commissioner Chopra In the Matter of Fresenius Medical Care AG & Co. KGaA and NxStage Medical, Inc.
Statement of Commissioner Slaughter In the Matter of Fresenius Medical Care AG & Co. KGaA and NxStage Medical, Inc.
Displaying 261 - 280 of 671